Showing results 1 to 5 of 5
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
Analysis of longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open label extension study Proceeding/Conference:Hepatology | 2020 | |||
Sulkowski, MSAgarwal, KFung, SKYuen, RMFMa, XLLalezari, JPNguyen, TTBae, HSSchiff, ERHassanein, THann, HWLElkhashab, MDieterich, DTKwo, PYNahass, RRamji, APark, JSRavendhran, NChan, SWeilert, FHan, SHBAyoub, WSGane, EJJacobson, IMBennett, MBonacini, MZayed, HAlves, KHuey, VHuang, QRuby, EQiang, DMKnox, SColonno, R | 2019 | 10 | ||
Long-term follow-up of entecavir treated protocol-defined non responders in rollover study ETV-901 Proceeding/Conference:Hepatology | 2007 | 69 | ||
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection Journal:New England Journal of Medicine | 2015 | 69 | ||
Sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in genotype 1, 2, 4, 5, 6 HCV patients: ASTRAL-1 study Proceeding/Conference:Hepatology International | 2016 | 91 |